Evidence map›Paper›PMID 40783180›Full record

ArticleJournal of the American Association for Laboratory Animal Science : JAALAS2025

Lessons Learned from Monitoring Adeno-Associated Virus-9 Neutralizing Antibody (AAV9-NAb) Seroconversion in a Cohort of Cynomolgus Macaques (Macaca fascicularis).

Rosemary V Santos, Arpana Khatri, Kate E Breyer, Jan Bernal, Judith Franco, Rajeev Dhawan, Conner Balzer, Marla Bazile, Maureen Hargaden, Mikele Simkins and 1 more

Abstract read
In one paragraph

Article in Journal of the American Association for Laboratory Animal Science : JAALAS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rosemary V Santos1Drug Safety Research and Development and Comparative Medicine, Pfizer Inc, Groton, Connecticut.
Arpana Khatri2Translational Sciences, Voyager Therapeutics, Cambridge, Massachusetts.
Kate E Breyer1Drug Safety Research and Development and Comparative Medicine, Pfizer Inc, Groton, Connecticut.
Jan Bernal3Comparative Medicine, Amgen Thousand Oaks, California.
Judith Franco1Drug Safety Research and Development and Comparative Medicine, Pfizer Inc, Groton, Connecticut.
Rajeev Dhawan4Research Animal Diagnostic Services, Charles River, Wilmington, Massachusetts; and.
Conner Balzer4Research Animal Diagnostic Services, Charles River, Wilmington, Massachusetts; and.
Marla Bazile1Drug Safety Research and Development and Comparative Medicine, Pfizer Inc, Groton, Connecticut.
Maureen Hargaden1Drug Safety Research and Development and Comparative Medicine, Pfizer Inc, Groton, Connecticut.
Mikele Simkins1Drug Safety Research and Development and Comparative Medicine, Pfizer Inc, Groton, Connecticut.
Suryanarayan Somananthan5Discovery and Translational Development, Solid Biosciences, Charlestown, Boston, Massachusetts.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this study was to track seroconversion in a cohort of 12, pair-housed, macaques that were previously screened negative for adeno-associated virus-9 neutralizing antibody (AAV9-NAb). Over a 6-month period, specific biosecurity strategies were implemented with the intention of understanding if following defined protocols could play a role in preservation of AAV9-NAb negative status. AAV9-NAb-negative animals were selected for shipment to the facility approximately 2 months after the initial screening. After arrival, animals were paired and housed in a single room with a dedicated housing corridor, cage wash, and equipment. They were then screened for AAV9-NAb status monthly by 2 different labs to confirm results and ascertain potential for variation of results. Upon initial screening at the facility (within one week of arrival), 2 of the 12 NHPs that were seronegative before shipment had seroconverted to AAV9-NAb positive status. The positive animals and their negative partners were moved to a different room but remained within the same isolated corridor with the same biosecurity practices. Serum that was taken on a monthly basis was also used to screen other AAVs. At the end of the 6-month period, AAV9 NAb status did not change from the time the animals were initially screened on site until the end of the study. Paired animals that were cohoused in the same cage with a positive partner did not seroconvert. Although a control group was not used to validate that biosecurity practices played a role in mitigating seroconversion, unpublished data from a facility employing less restricted biosecurity strategies suggest that the seroconversion process involves a more intricate process.

Indexed as

AAV, adeno-associated virusBAb(s), binding antibody/antibodiesCBC, complete blood countIgG, immunoglobulin GIgM, immunoglobulin MNAb(s), neutralizing antibody/antibodiesNHP(s), nonhuman primate(s)PK/PD, pharmacokinetics/pharmacodynamics

Identifiers

PMID40783180
PMCPMC12694322

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.